PathLang: A Language-Centered Benchmark for Vision-Language Models in Computational Pathology
Organizations: New York University, New York, NY, USA · Columbia University, New York, NY, USA · Weill Cornell Medicine, New York, NY, USA · Cornell University, Ithaca, NY, USA · University of British Columbia, Vancouver, BC, Canada · Vanderbilt University, Nashville, TN, USA · University of Pennsylvania, Philadelphia, PA, USA · Johns Hopkins University, Baltimore, MD, USA · New York Medical College, New York, NY, USA · BC Cancer Agency, Vancouver, BC, Canada · The University of Texas MD Anderson Cancer Center, Houston, TX, USA · Cornell Tech, New York, NY, USA
Abstract
Pathology vision-language models (VLMs) have shown strong visual perception ability, but their robustness in the language domain remains poorly characterized. Existing pathology VLM benchmarks largely rely on canonical closed-set prompts or perturb only generic templates, treating language as a fixed evaluation component rather than a variable axis of model behavior. In clinical practice, however, diagnostic language varies across reports, institutions, and candidate diagnoses. We introduce PathLang, a language-centered and clinically grounded zero-shot benchmark. PathLang holds the underlying slides, ground-truth labels, and image-text evaluation direction fixed while systematically varying only the diagnostic language, so that performance differences reflect how a diagnosis is phrased rather than what is imaged. The language variation follows how pathologists actually rephrase diagnoses (terminology, specificity, and reporting style), and all prompts and candidate pools are validated by six board-certified pathologists. PathLang covers four task families: (1) zero-shot classification with image-text alignment analysis, (2) cross-modal retrieval, (3) paraphrase robustness, including semantic-equivalence paraphrases, length and reporting-style variation, and prompt ensembling, and (4) open-vocabulary diagnosis retrieval over four candidate pools with distinct forms of semantic competition. Across nine VLMs and five public datasets spanning four organs, we find that performance is highly sensitive to clinically equivalent paraphrases, varies substantially across forms of semantic competition, and that image-text alignment quality does not necessarily translate into inter-class separability. We release the prompt corpus, candidate pools, pre-computed text embeddings, and evaluation code at https://anonymous.4open.science/r/PathLang.
Figures & tables
| Study | Cls. | I2I | I2T | T2I | Slide | Lang. Sens. | Clin. Valid. |
|---|---|---|---|---|---|---|---|
| MI-Zero [ 22 ] | ✓ | – | – | – | ✓ | – | – |
| PLIP [ 16 ] | ✓ | ✓ | – | ✓ | – | – | – |
| Quilt-1M [ 17 ] | ✓ | – | ✓ | ✓ | – | – | – |
| CONCH [ 21 ] | ✓ | – | ✓ | ✓ | ✓ | – | – |
| MUSK [ 32 ] | ✓ | ✓ | ✓ | ✓ | ✓ | – | – |
| Histo-VL [ 2 ] | ✓ | – | – | – | – | ✓ | – |
| Model | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acc | AUC | mF1 | Acc | AUC | mF1 | Acc | AUC | mF1 | Acc | AUC | mF1 | Acc | AUC | mF1 | |
| QuiltNet [ 17 ] | 0.402 | 0.561 | 0.287 | 0.072 | 0.528 | 0.034 | 0.127 | 0.542 | 0.109 | 0.577 | 0.546 | 0.389 | 0.169 | 0.534 | 0.106 |
| PLIP [ 16 ] | 0.561 | 0.565 | 0.550 | 0.323 | 0.528 | 0.212 | 0.250 | 0.506 | 0.088 | 0.603 | 0.390 | 0.505 | 0.376 | 0.529 | 0.199 |
| MI-Zero [ 22 ] | 0.407 | 0.461 | 0.292 | 0.176 | 0.494 | 0.084 | 0.160 | 0.493 | 0.090 | 0.444 | 0.331 | 0.325 | 0.152 | 0.478 | 0.145 |
| CONCH [ 21 ] | 0.578 | 0.527 | 0.423 | 0.629 | 0.502 | 0.199 | 0.140 | 0.496 | 0.108 | 0.458 | 0.487 | 0.399 | 0.097 | 0.495 | 0.080 |
| BiomedCLIP [ 35 ] | 0.612 | 0.505 | 0.451 | 0.557 | 0.499 | 0.198 | 0.271 | 0.498 | 0.071 | 0.577 | 0.546 | 0.389 | 0.038 | 0.470 | 0.017 |
| Models | CAMELYON16 | CAMELYON17 | PANDA | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L1 | L2 | L3 | L4 | L5 | L6 | L7 | L8 | L9 | L1 | L2 | L3 | L4 | L5 | L6 | L7 | L8 | L9 | L1 | L2 | L3 | L4 | L5 | L6 | L7 | L8 | L9 | |
| QuiltNet [ 17 ] | 0.472 | -00.1 | -07.6 | -07.3 | -10.2 | -12.7 | -14.5 | -14.8 | -14.8 | 0.165 | -27.2 | -32.0 | -36.9 | -42.4 | -47.8 | -48.6 | -53.3 | -56.2 | 0.185 | +03.4 | +00.7 | +06.2 | +05.2 | +13.2 | +17.6 | +19.3 | +24.9 |
| PLIP [ 16 ] | 0.543 | -05.0 | -04.7 | -08.6 | -07.2 | -08.6 | -05.2 | -07.7 | -10.1 | 0.229 | +04.1 | -02.4 | -09.5 | -14.9 | -18.8 | -24.7 | -24.9 | -28.3 | 0.265 | +03.7 | +06.2 | +07.1 | +06.3 | +05.9 | +05.2 | +04.1 | +03.5 |
| MI-Zero [ 22 ] | 0.481 | -00.1 | -04.3 | -04.9 | -07.3 | -09.3 | -10.7 | -11.7 | -11.9 | 0.189 | -23.0 | -19.3 | -31.9 | -34.0 | -36.4 | -37.3 | -37.8 | -37.4 | 0.158 | +04.4 | +03.7 | -03.7 | -08.4 | -08.9 | -14.9 | -12.7 | -17.4 |
| CONCH [ 21 ] | 0.431 | -00.8 | -01.0 | -04.6 | -06.5 | -06.8 | -06.8 | -06.7 | -06.7 | 0.323 | -08.9 | -25.1 | -18.4 | -22.6 | -26.4 | -27.7 | -34.6 | -60.3 | 0.179 | -01.1 | -07.5 | -09.8 | -08.2 | -11.5 | -18.9 | -10.3 | -10.4 |
| BiomedCLIP [ 35 ] | 0.520 | +04.1 | +03.5 | +03.8 | +07.4 | +11.3 | +14.4 | +15.1 | +15.1 | 0.363 | +15.7 | +31.9 | +34.9 | +57.7 | +63.2 | +72.5 | +75.0 | +75.0 | 0.162 | -00.5 | +00.7 | +00.3 | -03.9 | -05.4 | -06.0 | -08.7 | -14.2 |
Appendix figures & tables42 assets
Supplementary material from the paper’s appendix.
Appendix
| Model | Top 1% | Top 5% | Top 10% | Top 50% | Mean |
|---|---|---|---|---|---|
| BiomedCLIP | 0.214 | 0.220 | 0.252 | 0.176 | 0.218 |
| CONCH | 0.235 | 0.234 | 0.229 | 0.233 | 0.215 |
| KEEP | 0.277 | 0.300 | 0.314 | 0.270 | 0.268 |
| MI-Zero | 0.184 | 0.183 | 0.182 | 0.182 | 0.182 |
| MUSK | 0.285 | 0.281 | 0.277 | 0.261 | 0.284 |
| PathGen-CLIP | 0.248 | 0.241 | 0.242 | 0.245 | 0.245 |
| Top 1% | Top 5% | Top 10% | Top 50% | Mean | |
|---|---|---|---|---|---|
| Top 1% | 1.000 | 0.933 | 0.883 | 0.933 | 0.967 |
| Top 5% | 0.933 | 1.000 | 0.950 | 0.967 | 0.933 |
| Top 10% | 0.883 | 0.950 | 1.000 | 0.883 | 0.933 |
| Top 50% | 0.933 | 0.967 | 0.883 | 1.000 | 0.933 |
| Mean | 0.967 | 0.933 | 0.933 | 0.933 | 1.000 |
| Model | Top 1% | Top 5% | Top 10% | Top 50% | Mean |
|---|---|---|---|---|---|
| BiomedCLIP | 0.665 | 0.675 | 0.661 | 0.657 | 0.664 |
| CONCH | 0.684 | 0.685 | 0.689 | 0.664 | 0.672 |
| KEEP | 0.683 | 0.683 | 0.685 | 0.687 | 0.688 |
| MI-Zero | 0.642 | 0.638 | 0.638 | 0.635 | 0.640 |
| MUSK | 0.649 | 0.645 | 0.642 | 0.652 | 0.648 |
| PathGen-CLIP | 0.671 | 0.664 | 0.673 | 0.666 | 0.671 |
| Model | Top 1% | Top 5% | Top 10% | Top 50% | Mean |
|---|---|---|---|---|---|
| BiomedCLIP | 0.460 | 0.462 | 0.463 | 0.416 | 0.422 |
| CONCH | 0.492 | 0.449 | 0.443 | 0.366 | 0.347 |
| KEEP | 0.633 | 0.613 | 0.589 | 0.599 | 0.579 |
| MI-Zero | 0.413 | 0.381 | 0.399 | 0.403 | 0.390 |
| MUSK | 0.518 | 0.481 | 0.462 | 0.458 | 0.505 |
| PathGen-CLIP | 0.602 | 0.583 | 0.612 | 0.595 | 0.608 |
| Model | Top 1% | Top 5% | Top 10% | Top 50% | Mean |
|---|---|---|---|---|---|
| BiomedCLIP | 0.674 | 0.687 | 0.693 | 0.685 | 0.692 |
| CONCH | 0.715 | 0.749 | 0.764 | 0.774 | 0.785 |
| KEEP | 0.729 | 0.749 | 0.759 | 0.785 | 0.787 |
| MI-Zero | 0.683 | 0.680 | 0.682 | 0.692 | 0.686 |
| MUSK | 0.671 | 0.705 | 0.727 | 0.769 | 0.778 |
| PathGen-CLIP | 0.713 | 0.741 | 0.748 | 0.770 | 0.778 |
| Top 1% | Top 5% | Top 10% | Top 50% | Mean | |
|---|---|---|---|---|---|
| Top 1% | 1.000 | 0.833 | 0.933 | 0.800 | 0.850 |
| Top 5% | 0.833 | 1.000 | 0.917 | 0.767 | 0.833 |
| Top 10% | 0.933 | 0.917 | 1.000 | 0.783 | 0.833 |
| Top 50% | 0.800 | 0.767 | 0.783 | 1.000 | 0.983 |
| Mean | 0.850 | 0.833 | 0.833 | 0.983 | 1.000 |
| Top 1% | Top 5% | Top 10% | Top 50% | Mean | |
|---|---|---|---|---|---|
| Top 1% | 1.000 | 0.933 | 0.867 | 0.950 | 0.883 |
| Top 5% | 0.933 | 1.000 | 0.950 | 0.933 | 0.967 |
| Top 10% | 0.867 | 0.950 | 1.000 | 0.883 | 0.950 |
| Top 50% | 0.950 | 0.933 | 0.883 | 1.000 | 0.933 |
| Mean | 0.883 | 0.967 | 0.950 | 0.933 | 1.000 |
| Top 1% | Top 5% | Top 10% | Top 50% | Mean | |
|---|---|---|---|---|---|
| Top 1% | 1.000 | 0.933 | 0.883 | 0.817 | 0.633 |
| Top 5% | 0.933 | 1.000 | 0.950 | 0.917 | 0.833 |
| Top 10% | 0.883 | 0.950 | 1.000 | 0.900 | 0.783 |
| Top 50% | 0.817 | 0.917 | 0.900 | 1.000 | 0.917 |
| Mean | 0.633 | 0.833 | 0.783 | 0.917 | 1.000 |
| Model | Top 1% | Top 5% | Top 10% | Top 50% | Mean |
|---|---|---|---|---|---|
| BiomedCLIP | 0.338 | 0.332 | 0.335 | 0.334 | 0.334 |
| CONCH | 0.288 | 0.288 | 0.288 | 0.285 | 0.285 |
| KEEP | 0.480 | 0.482 | 0.484 | 0.484 | 0.482 |
| MI-Zero | 0.308 | 0.306 | 0.307 | 0.307 | 0.306 |
| MUSK | 0.347 | 0.335 | 0.332 | 0.321 | 0.300 |
| PathGen-CLIP | 0.394 | 0.407 | 0.416 | 0.422 | 0.424 |
| Top 1% | Top 5% | Top 10% | Top 50% | Mean | |
|---|---|---|---|---|---|
| Top 1% | 1.000 | 0.850 | 0.933 | 0.883 | 0.817 |
| Top 5% | 0.850 | 1.000 | 0.883 | 0.917 | 0.883 |
| Top 10% | 0.933 | 0.883 | 1.000 | 0.983 | 0.950 |
| Top 50% | 0.883 | 0.917 | 0.983 | 1.000 | 0.983 |
| Mean | 0.817 | 0.883 | 0.950 | 0.983 | 1.000 |
| Model | Top 1% | Top 5% | Top 10% | Top 50% | Mean |
|---|---|---|---|---|---|
| BiomedCLIP | 0.439 | 0.439 | 0.439 | 0.440 | 0.442 |
| CONCH | 0.338 | 0.344 | 0.345 | 0.340 | 0.332 |
| KEEP | 0.417 | 0.419 | 0.421 | 0.423 | 0.422 |
| MI-Zero | 0.295 | 0.297 | 0.296 | 0.299 | 0.298 |
| MUSK | 0.335 | 0.333 | 0.335 | 0.327 | 0.324 |
| PathGen-CLIP | 0.371 | 0.375 | 0.377 | 0.379 | 0.379 |
| Top 1% | Top 5% | Top 10% | Top 50% | Mean | |
|---|---|---|---|---|---|
| Top 1% | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Top 5% | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Top 10% | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Top 50% | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Mean | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Candidate set | Min. | Max. | Top- min. | Top- max. |
|---|---|---|---|---|
| Set 1: Open Vocabulary | 0.983 | 1.000 | 0.983 | 1.000 |
| Set 2: Label-Specific Mixture | 0.967 | 1.000 | 0.967 | 1.000 |
| Set 3: Cross-Organ | 1.000 | 1.000 | 1.000 | 1.000 |
| Set 4: All Datasets | 1.000 | 1.000 | 1.000 | 1.000 |
| Model | Hybrid Top-1% (query-dependent) | Mean Pooling (query-independent) | ||
|---|---|---|---|---|
| P.C. | PSS | P.C. | PSS | |
| BiomedCLIP | 0.004 | -0.118 | 0.004 | -0.124 |
| CONCH | 0.147 | -0.092 | 0.153 | -0.108 |
| KEEP | 0.295 | 0.142 | 0.308 | 0.113 |
| MI-Zero | 0.065 | -0.018 | 0.070 | -0.028 |
| MUSK | 0.128 | 0.063 | 0.155 | -0.048 |
| Model | Hybrid Top-1% (query-dependent) | Mean Pooling (query-independent) | ||
|---|---|---|---|---|
| P.C. | PSS | P.C. | PSS | |
| BiomedCLIP | 0.170 | -0.185 | 0.179 | -0.227 |
| CONCH | 0.026 | -0.167 | 0.075 | -0.165 |
| KEEP | 0.261 | 0.050 | 0.259 | 0.029 |
| MI-Zero | 0.107 | -0.125 | 0.115 | -0.141 |
| MUSK | 0.198 | 0.013 | 0.042 | -0.100 |
| Variation Type | Description |
|---|---|
| Synonym/Paraphrase | Semantically equivalent rewrites of the canonical class description |
| Length: Short | Concise, keyword-style prompt |
| Length: Medium | Moderately detailed prompt |
| Length: Long | Extended prompt with additional clinical context |
| Clinical Style | Formal clinical reporting style |
| Stage | Date | Description |
|---|---|---|
| Initial prompt set | Nov. 18, 2025 | Initial ground-truth/zero-shot prompts were generated and shared. |
| Distractor revision | Dec. 8, 2025 | A distractor-augmented prompt set was received; issues with the initial distractors were identified and revised. |
| Expert review | Apr. 9, 2026 | The submitted prompts were reviewed and revised by the clinical expert(s), and the revised prompt set was returned. |
| Post-review verification | Apr. 29, 2026 | The revised prompts were applied and tested, leading to identification of additional issues for correction. |
| Final revision | May 3, 2026 | A subsequent revised version incorporating the requested changes was received and used as the final prompt set. |
| Revision type | Original | Revised |
| Dysplasia terminology | low-grade cytologic atypia | low-grade cytologic dysplasia |
| severe epithelial atypia | severe epithelial dysplasia | |
| marked cytologic atypia | marked cytologic dysplasia | |
| mild atypia (colorectal adenoma) | mild dysplasia | |
| high-grade intraepithelial neoplasia | high-grade epithelial dysplasia | |
| tubular colorectal adenoma with mild dysplasia | tubular colorectal adenoma with low-grade dysplasia |
| Revision type | Original | Revised |
| Generic specific entity | reactive tissue | tubular adenoma |
| normal tissue | sessile serrated adenoma | |
| normal tissue | Barrett esophagus with low-grade dysplasia | |
| dysplasia | squamocolumnar mucosa with focal intestinal metaplasia | |
| benign tissue | squamocolumnar mucosa with focal intestinal metaplasia | |
| low-grade dysplasia | inflammatory polyp |
| Models | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Align. | Gap | Align. | Gap | Align. | Gap | Align. | Gap | Align. | Gap | |
| QuiltNet | 0.2332 | -0.0028 | 0.2395 | -0.0167 | 0.2451 | -0.0014 | 0.2718 | 0.0002 | 0.2756 | 0.0068 |
| PLIP | 0.2511 | 0.0011 | 0.2554 | 0.0058 | 0.2603 | 0.0043 | 0.2862 | -0.0003 | 0.2685 | 0.0046 |
| MI-Zero | -0.0044 | -0.0022 | -0.0232 | -0.0055 | -0.0500 | 0.0002 | 0.0391 | -0.0022 | 0.0510 | 0.0011 |
| CONCH | 0.0831 | -0.0074 | 0.0939 | -0.0066 | 0.0926 | -0.0058 | 0.0767 | -0.0067 | 0.0941 | -0.0069 |
| BiomedCLIP | 0.0051 | 0.0014 | 0.0138 | 0.0071 | 0.0111 | 0.0000 | -0.0040 | 0.0000 | -0.0233 | -0.0055 |
| Models | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | |
| QuiltNet | 0.538 | 0.874 | 0.680 | 0.718 | 0.595 | 0.872 | 0.712 | 0.742 | 0.661 | 0.893 | 0.761 | 0.786 | 0.917 | 0.973 | 0.943 | 0.949 | 0.468 | 0.806 | 0.612 | 0.640 |
| PLIP | 0.544 | 0.862 | 0.676 | 0.704 | 0.593 | 0.860 | 0.712 | 0.739 | 0.659 | 0.900 | 0.763 | 0.790 | 0.929 | 0.976 | 0.949 | 0.955 | 0.485 | 0.814 | 0.626 | 0.658 |
| MI-Zero | 0.475 | 0.879 | 0.640 | 0.682 | 0.511 | 0.868 | 0.656 | 0.694 | 0.319 | 0.729 | 0.495 | 0.533 | 0.867 | 0.950 | 0.906 | 0.914 | 0.494 | 0.819 | 0.636 | 0.666 |
| CONCH | 0.508 | 0.879 | 0.665 | 0.710 | 0.633 | 0.862 | 0.737 | 0.759 | 0.707 | 0.913 | 0.796 | 0.819 | 0.921 | 0.973 | 0.943 | 0.949 | 0.544 | 0.844 | 0.668 | 0.696 |
| BiomedCLIP | 0.491 | 0.882 | 0.653 | 0.696 | 0.505 | 0.856 | 0.662 | 0.701 | 0.332 | 0.737 | 0.508 | 0.545 | 0.846 | 0.952 | 0.894 | 0.905 | 0.447 | 0.823 | 0.607 | 0.648 |
| Models | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R@1 | MRR | nDCG | R@1 | MRR | nDCG | R@1 | MRR | nDCG | R@1 | MRR | nDCG | R@1 | MRR | nDCG | |
| QuiltNet | 0.500 | 0.728 | 0.798 | 0.397 | 0.618 | 0.713 | 0.186 | 0.421 | 0.559 | 0.467 | 0.699 | 0.775 | 0.194 | 0.430 | 0.567 |
| PLIP | 0.519 | 0.743 | 0.810 | 0.196 | 0.456 | 0.590 | 0.157 | 0.380 | 0.527 | 0.492 | 0.745 | 0.812 | 0.148 | 0.384 | 0.530 |
| MI-Zero | 0.563 | 0.781 | 0.838 | 0.192 | 0.385 | 0.527 | 0.194 | 0.404 | 0.543 | 0.501 | 0.731 | 0.801 | 0.122 | 0.354 | 0.506 |
| CONCH | 0.608 | 0.752 | 0.814 | 0.285 | 0.532 | 0.648 | 0.260 | 0.446 | 0.576 | 0.563 | 0.775 | 0.834 | 0.228 | 0.459 | 0.587 |
| BiomedCLIP | 0.509 | 0.752 | 0.817 | 0.303 | 0.568 | 0.676 | 0.114 | 0.322 | 0.479 | 0.524 | 0.762 | 0.824 | 0.198 | 0.448 | 0.582 |
| Models | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | R@1 | R@5 | MRR | nDCG | |
| QuiltNet | 0.625 | 1.000 | 0.781 | 0.803 | 0.438 | 0.813 | 0.533 | 0.601 | 0.250 | 0.542 | 0.326 | 0.384 | 0.625 | 0.750 | 0.688 | 0.695 | 0.250 | 0.667 | 0.388 | 0.460 |
| PLIP | 0.625 | 0.875 | 0.719 | 0.752 | 0.250 | 0.625 | 0.358 | 0.429 | 0.292 | 0.625 | 0.422 | 0.456 | 0.500 | 0.750 | 0.625 | 0.676 | 0.333 | 0.750 | 0.481 | 0.532 |
| MI-Zero | 0.500 | 0.500 | 0.500 | 0.500 | 0.250 | 0.625 | 0.385 | 0.438 | 0.208 | 0.500 | 0.291 | 0.347 | 0.500 | 0.500 | 0.500 | 0.500 | 0.208 | 0.458 | 0.300 | 0.330 |
| CONCH | 0.125 | 0.875 | 0.406 | 0.530 | 0.250 | 0.563 | 0.328 | 0.391 | 0.250 | 0.708 | 0.376 | 0.462 | 0.625 | 1.000 | 0.760 | 0.813 | 0.167 | 0.542 | 0.283 | 0.328 |
| BiomedCLIP | 0.750 | 1.000 | 0.800 | 0.828 | 0.188 | 0.688 | 0.359 | 0.443 | 0.292 | 0.542 | 0.375 | 0.386 | 0.500 | 0.875 | 0.598 | 0.665 | 0.208 | 0.250 | 0.208 | 0.205 |
| Model | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acc. | P.C. | PSS | Acc. | P.C. | PSS | Acc. | P.C. | PSS | Acc. | P.C. | PSS | Acc. | P.C. | PSS | |
| QuiltNet [ Ikezogwo et al., 2023 ] | 0.511 | 0.000 | -0.140 | 0.275 | 0.000 | -0.126 | 0.179 | 0.013 | -0.073 | 0.499 | 0.012 | -0.181 | 0.236 | 0.000 | -0.048 |
| PLIP [ Huang et al., 2023 ] | 0.513 | 0.010 | -0.073 | 0.236 | 0.002 | -0.068 | 0.198 | 0.000 | -0.055 | 0.536 | 0.196 | 0.080 | 0.196 | 0.000 | -0.087 |
| MI-Zero [ Lu et al., 2023 ] | 0.497 | 0.000 | -0.111 | 0.255 | 0.341 | 0.381 | 0.166 | 0.000 | -0.144 | 0.513 | 0.000 | -0.142 | 0.178 | 0.000 | -0.105 |
| CONCH [ Lu et al., 2024 ] | 0.498 | 0.724 | -0.026 | 0.263 | 0.000 | -0.139 | 0.198 | 0.000 | -0.082 | 0.513 | 0.011 | -0.149 | 0.160 | 0.017 | -0.072 |
| BiomedCLIP [ Zhang et al., 2024 ] | 0.495 | 0.000 | -0.184 | 0.246 | 0.000 | -0.211 | 0.165 | 0.000 | -0.137 | 0.492 | 0.025 | -0.115 | 0.174 | 0.000 | 0.058 |
| Models | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| v1 | v2 | v3 | v4 | v5 | v1 | v2 | v3 | v4 | v5 | v1 | v2 | v3 | v4 | v5 | v1 | v2 | v3 | v4 | v5 | v1 | v2 | v3 | v4 | v5 | |
| QuiltNet | 0.402 | 0.440 | 0.598 | 0.585 | 0.402 | 0.110 | 0.148 | 0.072 | 0.497 | 0.122 | 0.199 | 0.180 | 0.276 | 0.272 | 0.141 | 0.664 | 0.664 | 0.325 | 0.658 | 0.492 | 0.135 | 0.384 | 0.169 | 0.110 | 0.498 |
| PLIP | 0.619 | 0.406 | 0.521 | 0.579 | 0.486 | 0.345 | 0.188 | 0.186 | 0.383 | 0.150 | 0.279 | 0.254 | 0.301 | 0.295 | 0.267 | 0.445 | 0.521 | 0.525 | 0.542 | 0.532 | 0.430 | 0.494 | 0.502 | 0.477 | 0.144 |
| MI-Zero | 0.450 | 0.546 | 0.558 | 0.402 | 0.518 | 0.116 | 0.313 | 0.194 | 0.399 | 0.116 | 0.255 | 0.125 | 0.124 | 0.115 | 0.194 | 0.561 | 0.437 | 0.621 | 0.412 | 0.515 | 0.144 | 0.397 | 0.173 | 0.008 | 0.046 |
| CONCH | 0.420 | 0.402 | 0.397 | 0.440 | 0.402 | 0.142 | 0.090 | 0.122 | 0.485 | 0.505 | 0.132 | 0.157 | 0.278 | 0.117 | 0.135 | 0.547 | 0.454 | 0.476 | 0.509 | 0.535 | 0.084 | 0.131 | 0.089 | 0.190 | 0.089 |
| BiomedCLIP | 0.426 | 0.599 | 0.514 | 0.414 | 0.599 | 0.118 | 0.635 | 0.635 | 0.064 | 0.134 | 0.135 | 0.105 | 0.273 | 0.112 | 0.251 | 0.561 | 0.477 | 0.444 | 0.561 | 0.502 | 0.131 | 0.169 | 0.317 | 0.118 | 0.181 |
| Models | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Short | Medium | Long | Clinical | Short | Medium | Long | Clinical | Short | Medium | Long | Clinical | Short | Medium | Long | Clinical | Short | Medium | Long | Clinical | |
| QuiltNet | 0.402 | 0.402 | 0.598 | 0.402 | 0.074 | 0.116 | 0.170 | 0.072 | 0.115 | 0.164 | 0.190 | 0.119 | 0.665 | 0.459 | 0.577 | 0.577 | 0.152 | 0.110 | 0.283 | 0.160 |
| PLIP | 0.609 | 0.599 | 0.516 | 0.602 | 0.375 | 0.184 | 0.086 | 0.323 | 0.272 | 0.268 | 0.251 | 0.258 | 0.538 | 0.534 | 0.436 | 0.475 | 0.490 | 0.122 | 0.485 | 0.346 |
| MI-Zero | 0.452 | 0.548 | 0.414 | 0.407 | 0.419 | 0.072 | 0.118 | 0.118 | 0.242 | 0.124 | 0.160 | 0.155 | 0.568 | 0.440 | 0.345 | 0.570 | 0.000 | 0.173 | 0.152 | 0.549 |
| CONCH | 0.598 | 0.405 | 0.400 | 0.558 | 0.118 | 0.172 | 0.673 | 0.455 | 0.229 | 0.260 | 0.118 | 0.231 | 0.463 | 0.569 | 0.504 | 0.591 | 0.089 | 0.101 | 0.144 | 0.409 |
| BiomedCLIP | 0.599 | 0.579 | 0.399 | 0.599 | 0.619 | 0.635 | 0.072 | 0.619 | 0.272 | 0.126 | 0.148 | 0.120 | 0.561 | 0.561 | 0.439 | 0.556 | 0.511 | 0.485 | 0.473 | 0.485 |
| Model | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CI95-L | CI95-U | IQR | CI95-L | CI95-U | IQR | CI95-L | CI95-U | IQR | CI95-L | CI95-U | IQR | CI95-L | CI95-U | IQR | |
| QuiltNet [ Ikezogwo et al., 2023 ] | 0.3999 | 0.5346 | 0.0413 | 0.0708 | 0.2013 | 0.0359 | 0.1363 | 0.2572 | 0.0616 | 0.5509 | 0.6814 | 0.0482 | 0.1097 | 0.4412 | 0.1298 |
| PLIP [ Huang et al., 2023 ] | 0.3951 | 0.6096 | 0.1386 | 0.0913 | 0.3478 | 0.1288 | 0.2608 | 0.3084 | 0.0124 | 0.5274 | 0.6196 | 0.0382 | 0.2096 | 0.5038 | 0.1784 |
| MI-Zero [ Lu et al., 2023 ] | 0.4029 | 0.5349 | 0.0682 | 0.1047 | 0.2350 | 0.0253 | 0.1180 | 0.2219 | 0.0373 | 0.4108 | 0.6087 | 0.1056 | 0.0145 | 0.2152 | 0.0982 |
| CONCH [ Lu et al., 2024 ] | 0.3959 | 0.4756 | 0.0102 | 0.1041 | 0.5812 | 0.2186 | 0.1168 | 0.2455 | 0.0782 | 0.4619 | 0.5767 | 0.0586 | 0.0574 | 0.3534 | 0.0982 |
| BiomedCLIP [ Zhang et al., 2024 ] | 0.4593 | 0.6016 | 0.0823 | 0.2491 | 0.6353 | 0.2050 | 0.1165 | 0.2416 | 0.0586 | 0.4943 | 0.5614 | 0.0171 | 0.1305 | 0.4441 | 0.1924 |
| Model | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| P.C. | PSS | P.C. | PSS | P.C. | PSS | P.C. | PSS | P.C. | PSS | |
| QuiltNet | [0.000, 0.000] | [-0.151, -0.131] | [0.000, 0.000] | [-0.134, -0.118] | [0.011, 0.015] | [-0.076, -0.069] | [0.006, 0.019] | [-0.187, -0.174] | [0.000, 0.000] | [-0.070, -0.029] |
| PLIP | [0.003, 0.020] | [-0.089, -0.056] | [0.000, 0.006] | [-0.079, -0.058] | [0.000, 0.001] | [-0.059, -0.052] | [0.172, 0.218] | [0.059, 0.102] | [0.000, 0.000] | [-0.100, -0.075] |
| MI-Zero | [0.000, 0.000] | [-0.127, -0.095] | [0.303, 0.379] | [0.348, 0.414] | [0.000, 0.000] | [-0.145, -0.143] | [0.000, 0.000] | [-0.150, -0.135] | [0.000, 0.000] | [-0.131, -0.078] |
| CONCH | [0.681, 0.764] | [-0.049, -0.005] | [0.000, 0.000] | [-0.146, -0.133] | [0.000, 0.000] | [-0.085, -0.080] | [0.005, 0.017] | [-0.158, -0.142] | [0.004, 0.038] | [-0.092, -0.050] |
| BiomedCLIP | [0.000, 0.000] | [-0.193, -0.176] | [0.000, 0.000] | [-0.216, -0.207] | [0.000, 0.000] | [-0.138, -0.136] | [0.017, 0.035] | [-0.122, -0.107] | [0.000, 0.000] | [0.025, 0.086] |
| Model | CAMELYON16 | CAMELYON17 | PANDA | TCGA-GBMLGG | UniToPatho | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| P.C. | PSS | P.C. | PSS | P.C. | PSS | P.C. | PSS | P.C. | PSS | |
| QuiltNet | [0.000, 0.000] | [-0.333, -0.333] | [0.000, 0.000] | [-0.305, -0.290] | [0.000, 0.000] | [-0.205, -0.200] | [0.158, 0.204] | [-0.105, -0.055] | [0.000, 0.029] | [-0.137, -0.057] |
| PLIP | [0.386, 0.489] | [-0.051, 0.006] | [0.140, 0.202] | [0.076, 0.121] | [0.209, 0.225] | [-0.067, -0.060] | [0.034, 0.054] | [-0.116, -0.086] | [0.000, 0.000] | [-0.124, -0.077] |
| MI-Zero | [0.010, 0.040] | [-0.296, -0.249] | [0.313, 0.395] | [0.077, 0.145] | [0.000, 0.000] | [-0.127, -0.121] | [0.147, 0.186] | [-0.135, -0.109] | [0.000, 0.000] | [-0.282, -0.257] |
| CONCH | [0.000, 0.007] | [-0.301, -0.280] | [0.000, 0.000] | [-0.262, -0.250] | [0.000, 0.002] | [-0.114, -0.108] | [0.343, 0.394] | [0.019, 0.065] | [0.000, 0.000] | [-0.113, -0.076] |
| BiomedCLIP | [0.000, 0.000] | [-0.266, -0.253] | [0.000, 0.000] | [-0.322, -0.302] | [0.000, 0.000] | [-0.264, -0.259] | [0.000, 0.000] | [-0.269, -0.261] | [0.802, 0.894] | [0.046, 0.231] |
| Models | Mean | R@1 | R@2 | R@3 | R@4 | R@5 | R@6 | R@7 | R@8 | R@9 | R@10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMELYON16 | |||||||||||
| Chance | 0.275 | 0.050 | 0.100 | 0.150 | 0.200 | 0.250 | 0.300 | 0.350 | 0.400 | 0.450 | 0.500 |
| QuiltNet | 0.602 | 0.000 | 0.191 | 0.352 | 0.538 | 0.666 | 0.756 | 0.842 | 0.862 | 0.892 | 0.922 |
| PLIP | 0.478 | 0.005 | 0.007 | 0.085 | 0.251 | 0.451 | 0.584 | 0.732 | 0.830 | 0.902 | 0.932 |
| MI-Zero | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| CONCH | 0.313 | 0.073 | 0.143 | 0.201 | 0.347 | 0.384 | 0.395 | 0.395 | 0.397 | 0.397 | 0.397 |
| Models | Mean | R@1 | R@2 | R@3 | R@4 | R@5 |
|---|---|---|---|---|---|---|
| CAMELYON16 | ||||||
| QuiltNet | 0.253 | 0.000 | 0.010 | 0.395 | 0.402 | 0.460 |
| PLIP | 0.658 | 0.373 | 0.404 | 0.529 | 0.988 | 0.998 |
| MI-Zero | 0.328 | 0.000 | 0.179 | 0.222 | 0.502 | 0.735 |
| CONCH | 0.185 | 0.003 | 0.038 | 0.151 | 0.266 | 0.467 |
| BiomedCLIP | 0.384 | 0.000 | 0.123 | 0.599 | 0.599 | 0.599 |
| Models | Mean | R@1 | R@2 | R@3 | R@4 | R@5 |
|---|---|---|---|---|---|---|
| CAMELYON16 | ||||||
| QuiltNet | 0.630 | 0.191 | 0.374 | 0.668 | 0.915 | 1.000 |
| PLIP | 0.819 | 0.421 | 0.769 | 0.925 | 0.980 | 0.998 |
| MI-Zero | 0.335 | 0.000 | 0.253 | 0.384 | 0.432 | 0.606 |
| CONCH | 0.445 | 0.364 | 0.395 | 0.420 | 0.482 | 0.563 |
| BiomedCLIP | 0.029 | 0.000 | 0.000 | 0.003 | 0.028 | 0.115 |
| Models | Mean | R@1 | R@2 | R@3 | R@4 | R@5 | R@6 | R@7 | R@8 | R@9 | R@10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMELYON16 | |||||||||||
| QuiltNet | 0.604 | 0.000 | 0.018 | 0.384 | 0.422 | 0.530 | 0.686 | 0.995 | 1.000 | 1.000 | 1.000 |
| PLIP | 0.839 | 0.368 | 0.494 | 0.652 | 0.895 | 0.990 | 0.998 | 0.998 | 0.998 | 0.998 | 1.000 |
| MI-Zero | 0.477 | 0.000 | 0.091 | 0.114 | 0.217 | 0.543 | 0.644 | 0.689 | 0.760 | 0.828 | 0.881 |
| CONCH | 0.410 | 0.000 | 0.000 | 0.020 | 0.111 | 0.231 | 0.447 | 0.711 | 0.784 | 0.869 | 0.922 |
| BiomedCLIP | 0.123 | 0.000 | 0.000 | 0.000 | 0.005 | 0.015 | 0.033 | 0.045 | 0.118 | 0.499 | 0.519 |
| Label | Prompt |
|---|---|
| PANDA | |
| Grade 0 | Benign prostate tissue with normal gland architecture, uniform small glands, smooth luminal contours, and no nuclear atypia. Stroma is non-reactive and orderly. No evidence of carcinoma. |
| Grade 1 | Low-grade prostate cancer with well-formed glands. Tumor glands are still round, separate, and organized. Minimal infiltration into surrounding tissue. Mild nuclear atypia with recognizable glandular structures. No fused or cribriform patterns. |
| Grade 2 | Predominantly well-formed glands (pattern 3) with a lesser component of poorly formed or fused small glands (pattern 4). Early architectural disorder, some poorly formed glands beginning to appear. |
| Grade 3 | Predominantly poorly formed, fused, or cribriform glands (pattern 4) with a smaller component of well-formed glands (pattern 3). Architectural disorganization more prominent. Increased nuclear atypia. |
| Grade 4 | High-grade prostate cancer composed almost entirely of fused glands, poorly formed glands, or cribriform structures. Marked architectural disruption and significant nuclear atypia. No well-formed glands remain. |
| Label | Positive Prompts |
|---|---|
| PANDA | |
| Grade 0 | p1. Benign prostate tissue with normal gland architecture, uniform small glands, smooth luminal contours, and no nuclear atypia. Stroma is non-reactive and orderly. No evidence of carcinoma p2. benign prostate tissue with no evidence of carcinoma p3. non-neoplastic prostate glands with preserved architecture and no atypia p4. normal prostate glands without dysplasia or malignancy |
| Grade 1 | p1. Low-grade prostate cancer with well-formed glands. Tumor glands are still round, separate, and organized. Minimal infiltration into surrounding tissue. Mild nuclear atypia with recognizable glandular structures. No fused or cribriform patterns. p2. ISUP grade 1 prostate adenocarcinoma with well-formed, separate glands p3. Gleason score 3+3=6 prostate adenocarcinoma composed of round, discrete glands p4. low-grade prostate adenocarcinoma with minimal architectural distortion and mild atypia |
| Grade 2 | p1. Predominantly well-formed glands (pattern 3) with a lesser component of poorly formed or fused small glands (pattern 4). Early architectural disorder, some poorly formed glands beginning to appear. p2. ISUP grade 2 prostate adenocarcinoma with primary Gleason pattern 3 and secondary pattern 4 p3. Gleason score 3+4=7 prostate cancer with a minor component of poorly formed or fused glands p4. predominantly pattern 3 prostate adenocarcinoma with an admixed pattern 4 component |
| Grade 3 | p1. Predominantly poorly formed, fused, or cribriform glands (pattern 4) with a lesser component of well-formed glands (pattern 3). Architectural disorganization more prominent. Increased nuclear atypia. p2. ISUP grade 3 prostate adenocarcinoma with primary Gleason pattern 4 and secondary pattern 3 p3. Gleason score 4+3=7 prostate cancer dominated by poorly formed or fused glands p4. high-intermediate grade prostate adenocarcinoma with extensive pattern 4 architecture |
| Grade 4 | p1. High-grade prostate cancer composed almost entirely of fused glands, poorly formed glands, or cribriform structures. Marked architectural disruption and significant nuclear atypia. No well-formed glands remain. p2. ISUP grade 4 prostate adenocarcinoma composed almost entirely of Gleason pattern 4 p3. Gleason score 4+4=8 prostate cancer with fused and cribriform glands and no well-formed glands p4. high-grade prostate adenocarcinoma with diffuse cribriform and fused glandular growth |
| Label | Prompts |
|---|---|
| PANDA | |
| Grade 0 | v1. Normal prostate tissue v2. Non-neoplastic prostatic glands v3. Histologically normal prostate core v4. Prostate tissue without carcinoma v5. Prostatic tissue within normal limits |
| Grade 1 | v1. Well-formed low-grade prostate adenocarcinoma v2. Low-grade acinar carcinoma of prostate with individual discrete well-formed glands v3. Prostate carcinoma with well-formed glands v4. Well-differentiated prostate cancer v5. ISUP Grade 1 prostatic adenocarcinoma |
| Grade 2 | v1. Predominantly well-formed prostate adenocarcinoma with focal poorly formed glands v2. Predominantly well-formed prostate adenocarcinoma with minor component of poorly formed glands v3. Acinar prostate cancer with focal emerging fused glands v4. ISUP Grade 2 prostatic adenocarcinoma v5. Prostate tumor with minor poorly formed glands |
| Grade 3 | v1. Poorly formed gland-predominant prostate adenocarcinoma v2. Prostate carcinoma with predominantly fused and cribriform glands v3. Acinar prostate cancer with predominant poorly formed glands v4. ISUP Grade 3 prostatic adenocarcinoma v5. Prostate tumor with dominant poorly formed gland architecture |
| Grade 4 | v1. High-grade prostate carcinoma with exclusively poorly formed glands v2. Prostatic adenocarcinoma composed of fused and cribriform glands only v3. Poorly formed malignant prostatic glands without lower-grade component v4. High-grade acinar carcinoma in prostate tissue without well-formed glands v5. High-grade gland-forming prostate malignancy with cribriform architecture only |
| Label | Length | Prompt |
|---|---|---|
| PANDA | ||
| Grade 0 | short | ISUP Grade 0 (Benign) |
| medium | Benign prostatic tissue with preserved glandular architecture and bland cytology. | |
| long | Prostate core shows orderly non-neoplastic glands with smooth lumina, uniform epithelium, and no infiltrative or atypical features. | |
| clinical | Benign prostate tissue with normal gland architecture, uniform small glands, smooth luminal contours, and no nuclear atypia. Stroma is non-reactive and orderly. No evidence of carcinoma. | |
| Grade 1 | short | ISUP Grade 1 |
| Part I: Shared Candidate Pool | |
|---|---|
| benign tissue; low-grade malignancy; intermediate-grade malignancy; high-grade malignancy; poorly differentiated carcinoma; well-differentiated carcinoma; moderately differentiated carcinoma; adenocarcinoma; metastatic carcinoma; in situ carcinoma; dysplasia; low-grade dysplasia; high-grade dysplasia; invasive carcinoma; neuroendocrine carcinoma; squamous cell carcinoma; small cell carcinoma; undifferentiated carcinoma; tubular adenoma; sessile serrated adenoma. | |
| Part II: Dataset-specific Ground Truth Mapping | |
| Dataset Label | Ground Truth Candidate |
| PANDA | |
| Grade 0 | benign tissue |
| Grade 1 | low-grade malignancy |
| Label | Ground Truth | Candidate Pool |
|---|---|---|
| PANDA | ||
| Grade 0 | benign prostate tissue | benign prostate tissue; ISUP Grade 1 prostate cancer; ISUP Grade 2 prostate cancer; normal colon tissue; benign colorectal mucosa; normal lymph node; benign breast tissue; normal liver; normal lung tissue; benign thyroid tissue |
| Grade 1 | ISUP Grade 1 prostate cancer | ISUP Grade 1 prostate cancer; benign prostate tissue; ISUP Grade 2 prostate cancer; ISUP Grade 3 prostate cancer; low-grade tubular adenoma; low-grade glioma; tubular adenoma low-grade; lymph node micrometastasis; low-grade dysplasia; high grade prostatic intraepithelial neoplasia (HGPIN) |
| Grade 2 | ISUP Grade 2 prostate cancer | ISUP Grade 2 prostate cancer; ISUP Grade 1 prostate cancer; ISUP Grade 3 prostate cancer; ISUP Grade 4 prostate cancer; tubular adenoma high-grade; tubular adenoma low-grade; moderately differentiated carcinoma; intermediate grade dysplasia; lymph node micrometastasis; lymph node macrometastasis |
| Grade 3 | ISUP Grade 3 prostate cancer | ISUP Grade 3 prostate cancer; ISUP Grade 2 prostate cancer; ISUP Grade 4 prostate cancer; ISUP Grade 5 prostate cancer; tubular adenoma high-grade; tubulovillous adenoma high-grade; high-grade dysplasia; HGPIN; poorly differentiated carcinoma; lymph node macrometastasis |
| Grade 4 | ISUP Grade 4 prostate cancer | ISUP Grade 4 prostate cancer; ISUP Grade 3 prostate cancer; ISUP Grade 5 prostate cancer; ISUP Grade 2 prostate cancer; tubulovillous adenoma high-grade; glioblastoma; high-grade dysplasia; well differentiated carcinoma; lymph node macrometastasis; HGPIN |
| Label | Ground Truth | Label-specific Candidate(s) |
|---|---|---|
| PANDA | ||
| Shared candidate pool: glioblastoma; low-grade glioma; lymph node metastasis; normal lymph node; colon adenocarcinoma; normal colon tissue; breast carcinoma; normal lung tissue; benign prostate tissue | ||
| Grade 0 | benign prostate tissue | benign prostate tissue |
| Grade 1 | ISUP Grade 1 prostate cancer | ISUP Grade 1 |
| Grade 2 | ISUP Grade 2 prostate cancer | ISUP Grade 2 |
| Grade 3 | ISUP Grade 3 prostate cancer | ISUP Grade 3 |
| Part I: Shared Candidate Pool | |
| benign prostate tissue; ISUP Grade 1 prostate cancer; ISUP Grade 2 prostate cancer; ISUP Grade 3 prostate cancer; ISUP Grade 4 prostate cancer; ISUP Grade 5 prostate cancer; normal colon tissue; hyperplastic polyp; tubular adenoma low-grade; tubular adenoma high-grade; tubulovillous adenoma low-grade; tubulovillous adenoma high-grade; normal lymph node; lymph node metastasis; lymph node isolated tumor cells; lymph node micrometastasis; lymph node macrometastasis; low-grade glioma; glioblastoma. | |
| Part II: Dataset-specific Ground Truth Mapping | |
| Label | Ground Truth |
| PANDA | |
| Grade 0 | benign prostate tissue |
| Grade 1 | ISUP Grade 1 prostate cancer |